An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Trial Status: active
Researchers are looking for new ways to treat metastatic castration-resistant prostate
cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan
(also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if
people who receive I-DXd live longer overall and live longer without the cancer growing
or spreading than people who receive chemotherapy,
Inclusion Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has diagnosis of metastatic castration-resistant prostate cancer (mCRPC)
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post
bilateral orchiectomy) within 6 months prior to entering the study
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI)
and progressed during or after at least 8 weeks of treatment
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that
required steroids
- Has uncontrolled or significant cardiovascular disease
- Has received prior treatment with a taxane-based chemotherapy agent for mCRPC
Additional locations may be listed on ClinicalTrials.gov for NCT06925737.
